Skip to content

Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study

Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02029469
Enrollment
59
Registered
2014-01-08
Start date
2007-10-31
Completion date
2014-07-31
Last updated
2014-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Deformity of Head, Post-traumatic Arthrosis of Other Joints, Shoulder Region, Rheumatoid Arthritis Shoulder, Shoulder Arthritis Osteoarthritis

Keywords

Humeral Resurfacing, Humeral Resurfacing Arthroplasty

Brief summary

It is a non-randomized, consecutive enrollment, 10-year follow-up study of patients who are treated with the Ascension® HRA. Its purpose is to measure and document the outcomes associated with implanting the Ascension HRA prosthesis. Patients will be periodically assessed to collect data related to safety and effectiveness endpoints at the following intervals: preoperative, surgery/immediate post-op, 3 months, 6 months, 1 year, 2 year, 5 year, and 10 years.

Detailed description

At each assessment interval, information on complications and adverse events will be collected. In addition, shoulder joint range of motion will be collected, and implants will be evaluated radiographically to determine joint position and assess implant with regards to radiolucencies, subsidence and subluxation (migration). Patient satisfaction with regard to the effect of the implant on shoulder function, joint pain, and overall satisfaction will be assessed using a visual analog scale (VAS). Furthermore, if there are any implant revisions during the 10-year follow-up for any of the patients enrolled in the study, the implant and/or surrounding tissue will be harvested if possible and submitted for histopathological examination.

Interventions

DEVICEAscension HRA device

Patients who are treated with the Ascension® HRA for resurfacing of humeral head.

Sponsors

Ascension Orthopedics, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* The following patient will be included in the study - Patient who: * Is treated with the Ascension HRA; * Is disabled by either non-inflammatory or inflammatory arthritis (i.e. rheumatoid arthritis, osteoarthritis and avascular necrosis; * Has mild or moderate humeral head deformity and /or limited motion; * Has post-traumatic arthritis; * Has an intact or reparable rotator cuff; * Has the means and ability to return for all required study visits * Is willing to participate in the study; * Has signed an Informed Consent Form; * Is at least 18 years of age and skeletally mature at the time of surgery; * Is less than 75 years of age at the time of surgery

Exclusion criteria

The following patients will be excluded from the study - Patients who: * Infection, sepsis, and osteomyelitis; * Osteoporosis; * Metabolic disorders which may impair bone formation; * Osteomalacia; * Rapid joint destruction, marked bone loss or bone resorption apparent on X-ray; * Revision procedures where other devices or treatments have failed * Refuses to be in the study; or does not have the means and ability to return for all required study visits; * Currently participating in another clinical study.

Design outcomes

Primary

MeasureTime frameDescription
American Shoulder and Elbow Surgeon ScoreOutcome data will be evaluated at 2 yearsThe ASES score will be evaluated at 2 years and compared to baseline.

Secondary

MeasureTime frameDescription
Range of Motion2 yearsShoulder range of motion will be measured compared to baseline.
VAS scale for pain2 yearsVAS score for pain will be evaluated at 2 years and compared to baseline.
AP and axillary radiographs2 yearsRadiographs will be evaluated at 2 years for subsidence, lucent lines and evidence of movement or pending failure.
Adverse events2 years and during entire trialAEs will be assessed at each study timepoint

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026